Pasithea Therapeutics (KTTA) Insider Trading & Ownership $1.40 -0.12 (-7.89%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.48 +0.08 (+5.43%) As of 05/2/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Pasithea Therapeutics (NASDAQ:KTTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.30%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$347,953.20Number OfInsiders Selling(Last 3 Years)0 Get KTTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Pasithea Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KTTA Insider Buying and Selling by Quarter Pasithea Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/2/2023Lawrence SteinmanDirectorBuy1,500$8.60$12,900.00 10/17/2022David DelaneyMajor ShareholderBuy50$22.20$1,110.00 9/28/2022Eric ShahinianMajor ShareholderBuy2,882$23.80$68,591.60 8/29/2022Eric ShahinianMajor ShareholderBuy250$23.40$5,850.00 8/19/2022Avi GellerMajor ShareholderBuy2,732$26.00$71,032.00 8/17/2022Eric ShahinianMajor ShareholderBuy7,788$24.20$188,469.60 (Data available from 1/1/2013 forward) KTTA Insider Trading Activity - Frequently Asked Questions Who is on Pasithea Therapeutics's Insider Roster? The list of insiders at Pasithea Therapeutics includes Avi Geller, David Delaney, Eric Shahinian, and Lawrence Steinman. Learn more on insiders at KTTA. What percentage of Pasithea Therapeutics stock is owned by insiders? 16.30% of Pasithea Therapeutics stock is owned by insiders. Learn more on KTTA's insider holdings. Which Pasithea Therapeutics insiders have been buying company stock? The following insider purchased KTTA shares in the last 24 months: Lawrence Steinman ($12,900.00). How much insider buying is happening at Pasithea Therapeutics? Insiders have purchased a total of 1,500 KTTA shares in the last 24 months for a total of $12,900.00 bought. Pasithea Therapeutics Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder, MD & Executive Chairman Compensation: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Compensation: $480kMr. Daniel H. Schneiderman (Age 46)Chief Financial Officer Compensation: $345.94kDr. Graeme Currie Ph.D. (Age 57)Chief Development Officer Compensation: $346.62kDr. Yassine Bendiabdallah Ph.D. (Age 40)COO & Head of UK Clinics More Insider Trading Tools from MarketBeat Related Companies Equillium Insider Selling Unity Biotechnology Insider Selling Cingulate Insider Selling Edesa Biotech Insider Selling Lipocine Insider Selling Bullfrog AI Insider Selling BioVie Insider Selling GlycoMimetics Insider Selling Moleculin Biotech Insider Selling MIRA Pharmaceuticals Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:KTTA) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTA Stock Free KTTA Stock Alerts